Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
198 results
  • Novel Cytogenetic Characterization of Pleomorphic Hyalinizing Angiectatic Tumor (PHAT). [Journal Article]
    J Assoc Genet Technol 2019; 45(3):116-120Rankins C, Covington JD, … Gardner JA
  • Pleomorphic hyalinizing angiectatic tumor (PHAT) is a rare soft tissue tumor that, despite its characteristic marked pleomorphism, is slow growing and of intermediate grade malignancy. PHAT is not known to metastasize, but is locally aggressive with a post-excision recurrence rate of up to 50%. Two other soft tissue tumors, hemosiderotic fibrolipomatous tumor (HFLT) and myxoinflammatory fibroblas…
  • LEFKOTHEA Regulates Nuclear and Chloroplast mRNA Splicing in Plants. [Journal Article]
    Dev Cell 2019; 50(6):767-779.e7Daras G, Rigas S, … Hatzopoulos P
  • Eukaryotic organisms accomplish the removal of introns to produce mature mRNAs through splicing. Nuclear and organelle splicing mechanisms are distinctively executed by spliceosome and group II intron complex, respectively. Here, we show that LEFKOTHEA, a nuclear encoded RNA-binding protein, participates in chloroplast group II intron and nuclear pre-mRNA splicing. Transiently optimized LEFKOTHEA…
  • Pleomorphic hyalinizing angiectatic tumor of the mesorectum: a rare case and review of literature. [Case Reports]
    Autops Case Rep 2019 Jul-Sep; 9(3):e2019097Balasubiramaniyan V, Muduly D, … Das PK
  • Pleomorphic hyalinizing angiectatic tumor (PHAT) is a rare tumor of uncertain tissue origin. Although it has been classified as a benign tumor under the WHO classification, it is locally aggressive, and multiple recurrences have been reported. PHAT commonly involves the lower extremities; however, various unusual sites of origin have been reported. We present the case of a 30-year-old female with…
  • Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. [Journal Article]
    Cancer Discov 2019; 9(10):1372-1387Farago AF, Yeap BY, … Drapkin BJ
  • Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in patients with previously treated SCLC. We established a recommended phase II dose of olaparib 200 mg orally twice daily with temozolomide 75 mg/m2 daily, both on days 1 to 7 of a 21-day cyc…
  • Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. [Journal Article]
    Cell 2019; 177(7):1903-1914.e14Yan C, Brunson DC, … Langenau DM
  • Xenograft cell transplantation into immunodeficient mice has become the gold standard for assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell phenotypes is difficult. Here, we report an optically-clear prkdc-/-, il2rga-/- zebrafish that lacks adaptive and natural killer immune cells, can engraft a wide array of human cancers at 37°C, and permits the dynamic vi…
New Search Next